Adapting the Abbreviated Impactor Measurement (AIM) concept to make appropriate inhaler aerosol measurements to compare with clinical data: A scoping study with the "alberta" idealized throat (AIT) inlet

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 25, Issue 4, 2012, Pages 188-197

  Mitchell, Jolyon ^a   Copley, Mark ^b   Sizer, Yvonne ^c   Russell, Theresa ^c   Solomon, Derek ^c  

^a TRUDELL MEDICAL INTERNATIONAL   (Canada)

^b Copley Scientific Ltd ^*  (United Kingdom)

^c Melbourn Scientific Ltd   (United Kingdom)

Author keywords

abbreviated testing; cascade impactor; clinically relevant data; inhaler

Indexed keywords

EVOHALER; SALBUTAMOL; UNCLASSIFIED DRUG;

ABBREVIATED IMPACTOR MEASUREMENT; AEROSOL; ANALYSIS OF VARIANCE; ARTICLE; CLINICAL STUDY; CONTROLLED STUDY; DRUG QUALITY; IN VITRO STUDY; LUNG; METERED DOSE INHALER; OROPHARYNX; PHARMACOLOGICAL PARAMETERS; STATISTICAL SIGNIFICANCE;

ADMINISTRATION, INHALATION; ADULT; AEROSOLS; ALBUTEROL; BRONCHODILATOR AGENTS; EQUIPMENT DESIGN; HUMANS; METERED DOSE INHALERS; MODELS, ANATOMIC; MODELS, BIOLOGICAL; PARTICLE SIZE; QUALITY CONTROL; RESPIRATORY SYSTEM; TECHNOLOGY, PHARMACEUTICAL;

EID: 84864714719     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2011.0925     Document Type: Article

References (30)

1. Christopher D, Curry P, Doub B, Furnkranz K, Lavery M, Lin K, Lyapustina S, Mitchell J, Rogers B, Strickland H, Tougas T, Tsong Y, and Wyka B: Considerations for the development and practice of cascade impaction testing including a mass balance failure investigation tree. J Aerosol Med. 2003;16:235-247.
2. Bonam M, Christopher D, Cipolla D, Donovan B, Goodwin D, Holmes S, Lyapustina S, Mitchell J, Nichols S, Petterson G, Quale C, Rao N, Singh D, Tougas T, Van Oort M, Walther B, and Wyka B: Minimizing variability of cascade impaction measurements in inhalers and nebulizers. AAPS PharmSci-Tech. 2008;9:404-413.
3. Dunbar C, and Mitchell JP: Analysis of cascade impactor mass distributions. J. Aerosol Med. 2005;18:439-451.
4. Mitchell JP, Newman SP, and Chan H-K: In vitro and in vivo aspects of cascade impactor tests and inhaler performance: a review. AAPS PharmSciTech. 2007;8:Article 110; available on-line at URL: http://www.aapspharmscitech.org/ articles/pt0804/pt0804110/pt0804110.pdf. visited November 21, 2011.
5. Tougas TP, Christopher D, Mitchell JP, Strickland H, Wyka B, Van Oort M, and Lyapustina S: Improved quality control metrics for cascade impactionmeasurements of orally inhaled drug products (OIPs). AAPS PharmSciTech. 2009;10:1276-1285.
6. Tougas TP, Christopher JD, Mitchell JP, and Lyapustina S: Efficient data analysis and abbreviated impactor measure- ment concepts. In: RN Dalby, PR Byron J Peart, JD Suman, SJ Farr, and PM Young (eds). Respiratory Drug Delivery 2010. Davis Healthcare International Publishing, River Grove, IL; pp.599-603, 2010.
7. European Directorate for the Quality of Medicines and Healthcare (EDQM): Section 2.9.18-Preparations for Inhalation: Aerodynamic Assessment of Fine Particles. European Pharmacopeia 6th Ed, Strasbourg, France: Council of Europe; pp. 287-300, 2009.
8. Dolovich MB, and Mitchell JP: Canadian Standards Association standard CAN/CSA/Z264.1-02:2002: A new voluntary standard for spacers and holding chambers used with pressurized metered-dose inhalers. Can Respir J. 2004;11: 489-495.
9. Vanden Burgt JA, Busse WW, Martin RJ, Szefler SJ, and Donnell D: Efficacy and safety overview of a new inhaled corticosteroid, QVAR (hydrofluoroalkane- beclomethasone extrafine inhalation aerosol), in asthma. J Allergy Clin Immunol. 2000;106:1209-1226.
10. Mitchell JP, and Nichols SC: Summary of abbreviated impactor measurement workshop organized by the European Pharmaceutical Aerosol Group, 8 December 2010. Ther Deliv 2011;2:307-310.
11. Mitchell JP, Nagel MW, Doyle C, Ali RS, Avvakoumova V, Christopher JD, Quiroz J, Strickland H, Tougas T, and Lyapustina S: Relative precision of inhaler aerodynamic particle size distribution (APSD) metrics by full resolution and abbreviated Andersen cascade impactors (ACIs): Part 1. AAPS PharmSciTech. 2010;11:843-851.
12. Mitchell JP, Nagel MW, Doyle C, Ali RS, Avvakoumova V, Christopher D, Quiroz J, Strickland H, Tougas T, and Lyapustina S: Relative precision of inhaler aerodynamic particle size distribution (APSD) metrics by full resolution and abbreviated Andersen cascade impactors (ACIs): part 2-investigation of bias in extra-fine mass fraction with AIMHRT impactor. AAPS PharmSciTech. 2010;11:1115-1118.
13. Mitchell JP, and Nagel MW: Cascade impactors for the size characterization of aerosols from medical inhalers: their uses and limitations. J Aerosol Med. 2003;16:341-377.
14. Zhang Y, Gilbertson K, and Finlay WH: In vivo-in vitro comparison of deposition in three mouth-throat models with Qvar- and Turbuhaler- inhalers. J Aerosol Med. 2007;20:227-235.
15. Zhang Y, and Finlay WH: Experimental measurements of particle deposition in three proximal lung bifurcation models with an idealized mouth-throat. J Aerosol Med. 2005;18:460-473.
16. Kwok PCL, Glover W, and Chan H-K: Electrostatic charge characteristics of aerosols produced from metered dose inhalers. J Pharm Sci. 2005;4:2789-2799.
17. Stapleton KW, Guentsch E, Hoskinson MK, and Finlay WH: On the suitability of k-turbulence modeling for aerosol deposition in the mouth and throat: a comparison with experiment. J Aerosol Sci. 2000;31:731-749.
18. Grgic B, Finlay WH, and Heenan AF: Regional aerosol deposition and flow measurements in an idealized mouth and throat. J Aerosol Sci. 2004;35:21-32.
19. Grgic B, Finlay WH, Burnell PKP, and Heenan A: In vitro intersubject and intersubject deposition measurements in realistic mouth-throat geometries. J Aerosol Sci. 2004;35: 1025-1040.
20. Zhou Y, Sun J, and ChengY-S:Comparison of deposition in the USP and physical mouth-throat models with solid and liquid particles. J Aerosol Med Pulmon Deliv. 2011;24:277-284.
21. Ehtezazi T, Saleem I, Shrubb I, Allanson ID, and O'Callaghan C: The interaction between the oropharyngeal geometry and aerosols via pressurized metered dose inhalers. Pharm Res. 2010;27:175-186.
22. Mitchell JP, Nagel MW, Avvakoumova V, MacKay H, and Ali R: The abbreviated impactor measurement (AIM) concept: part 1-influence of particle bounce and re-entrainment-evaluation with a dry pressurized metered dose inhaler (pMDI)-based formulation. AAPS PharmSciTech. 2009;10:243-251.
23. Mitchell JP, Nagel MW, Avvakoumova V, MacKay H, and Ali R: The abbreviated impactor measurement (AIM) concept: part 2-influence of evaporation of a volatile component-evaluation with a droplet producing'' pressurized metered dose inhaler (pMDI)-based formulation containing ethanol as co-solvent. AAPS PharmSciTech. 2009;10:252-257.
24. Copley M, Mitchell J, and Solomon D: Evaluating the Alberta throat: an innovation to support the acquisition of more clinically applicable aerosol aerodynamic particle size distribution (APSD) data in oral inhaled product (OIP) development. Inhalation. 2011;5:12-16.
25. Nichols S: Particle size distribution parameters using the Next Generation Pharmaceutical Impactor. In: RN Dalby, PR Byron, J Peart, JD Suman, and SJ Farr (eds). Respiratory Drug Delivery-IX. Davis HealthCare Int. Publishing, River Grove, IL; pp. 485-487, 2004.
26. FDA CDER: Draft guidance for industry metered dose inhaler (MDI) and dry powder inhaler (DPI) drug products chemistry, manufacturing, and controls documentation. 1998. Available at: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM070573.pdf Accessed 18 Aug 2011.
27. Roberts DL, and Mitchell JP: Influence of stage efficiency curves on interpretation of abbreviated impactor data. Drug Delivery to the Lungs 22, The Aerosol Society, Edinburgh, UK; pp. 177-180, 2011.
28. Marple, VA, Olson BA, Santhanakrishnan K, Mitchell JP, Murray S, and Hudson-Curtis B: Next Generation Pharmaceutical Impactor. Part II: Calibration. J. Aerosol Med. 2003;16:301-324.
29. Smyth HDC, Evans RM, and Hickey AJ: Aerosol generation from propellant-driven metered dose inhalers. In: AJ Hickey (ed). Inhalation Aerosols: Physical and Biological Basis for Therapy. Informa Healthcare, New York; pp. 399-416, 2007.
30. Newman SP, and Chan H-K: In vitro/in vivo comparisons in pulmonary drug delivery. J Aerosol Med. 2008;21:1-8.